Ind-Swift Laboratories Ltd. (IN:INDSWFTLAB)
:INDSWFTLAB
Want to see IN:INDSWFTLAB full AI Analyst Report?
INDSWFTLAB Stock Chart & Stats
₹90.70
-₹2.17(-1.99%)
At close: 4:00 PM EST
₹90.70
-₹2.17(-1.99%)
Day’s Range― - ―
52-Week Range₹87.00 - ₹173.50
Previous CloseN/A
Volume31.71K
Average Volume (3M)7.30K
Market Cap
₹14.15B
Enterprise Value₹8.99B
Total Cash (Recent Filing)₹4.33B
Total Debt (Recent Filing)₹220.47M
Price to Earnings (P/E)32.9
Beta0.93
Next Earnings
Aug 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)44.44
Shares Outstanding86,836,555
10 Day Avg. Volume7,859
30 Day Avg. Volume7,299
Financial Highlights & Ratios
PEG Ratio-0.31
Price to Book (P/B)0.79
Price to Sales (P/S)1.71
P/FCF Ratio-10.22
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Reduced Leverage And Stronger Capital BaseThe company materially lowered leverage and grew equity through 2024–2026, creating a stronger capital base that reduces refinancing risk and improves financial flexibility. This durable improvement provides room to fund restructuring or targeted investments without immediate liquidity stress, though one-time actions should be monitored.
Prior Revenue And Profit Growth Track RecordHistorically the business demonstrated the ability to grow revenue and restore profitability, indicating underlying commercial capability and product demand. That track record suggests the firm can recover operationally if it addresses the drivers of recent declines, supporting medium-term recovery potential versus companies without prior performance consistency.
Demonstrated Prior Cash-generation CapabilityOperating cash flow was solidly positive through 2021–2023, demonstrating the business can convert earnings into cash under favorable conditions. This historical cash-generation ability implies the recent cash deficits may be cyclical or remediable through operational fixes, helping long-term viability if management restores conversion.
Bears Say
Three Consecutive Years Of Negative Operating/free Cash FlowPersistent negative operating and free cash flow over multiple years drains liquidity and forces reliance on balance-sheet measures or external funding. This structural cash shortfall constrains investment, capital allocation, and buffer against shocks, increasing refinancing and execution risk unless cash conversion is sustainably restored.
Sharp Recent Revenue ContractionA multi-year top-line decline culminating in a ~22% drop in 2026 weakens operating leverage and market positioning. Sustained revenue loss reduces scale benefits and margin resilience, complicates recovery planning, and implies customers or product mix issues that may take several quarters to address, harming medium-term earnings potential.
Volatile Profitability And Earnings-to-cash Conversion MismatchProfitability has swung materially year-to-year while cash conversion has deteriorated, creating earnings quality concerns. When reported profits do not convert to cash, forecasting and capital allocation become less reliable, increasing the risk that apparent profits mask underlying operational issues needing structural fixes.
Ind-Swift Laboratories Ltd. News
INDSWFTLAB FAQ
What was Ind-Swift Laboratories Ltd.’s price range in the past 12 months?
Ind-Swift Laboratories Ltd. lowest stock price was ₹87.00 and its highest was ₹173.50 in the past 12 months.
What is Ind-Swift Laboratories Ltd.’s market cap?
Ind-Swift Laboratories Ltd.’s market cap is ₹14.15B.
When is Ind-Swift Laboratories Ltd.’s upcoming earnings report date?
Ind-Swift Laboratories Ltd.’s upcoming earnings report date is Aug 12, 2026 which is in 58 days.
How were Ind-Swift Laboratories Ltd.’s earnings last quarter?
Ind-Swift Laboratories Ltd. released its earnings results on May 28, 2026. The company reported ₹1.81 earnings per share for the quarter, beating the consensus estimate of N/A by ₹1.81.
Is Ind-Swift Laboratories Ltd. overvalued?
According to Wall Street analysts Ind-Swift Laboratories Ltd.’s price is currently Overvalued.
Does Ind-Swift Laboratories Ltd. pay dividends?
Ind-Swift Laboratories Ltd. pays a Annually dividend of ₹1 which represents an annual dividend yield of N/A. See more information on Ind-Swift Laboratories Ltd. dividends here
What is Ind-Swift Laboratories Ltd.’s EPS estimate?
Ind-Swift Laboratories Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Ind-Swift Laboratories Ltd. have?
Ind-Swift Laboratories Ltd. has 86,836,555 shares outstanding.
What happened to Ind-Swift Laboratories Ltd.’s price movement after its last earnings report?
Ind-Swift Laboratories Ltd. reported an EPS of ₹1.81 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Ind-Swift Laboratories Ltd.?
Currently, no hedge funds are holding shares in IN:INDSWFTLAB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Ind-Swift Laboratories Ltd.
Ind-Swift Laboratories Limited, an Indian enterprise, is engaged in the development, production, and distribution of active pharmaceutical ingredients (APIs). The company's comprehensive API portfolio addresses numerous therapeutic domains, including macrolide antibiotics, cardiovascular ailments, antihistamines, antidiabetics, antipsychotics, bone resorption inhibitors, antimigraine treatments, Parkinson's disease, hyperparathyroidism, analgesics, aromatase inhibitors, nootropics, antidiarrhoeal/antiprotozoal conditions, anticholinergics, sedatives, hypnotics, alcohol abstinence, antineoplastics, and solutions for ADHD symptoms. Additionally, Ind-Swift supplies reference standards and impurities for a long list of specific compounds such as acamprosate calcium, anastrozole, aripiprazole, atorvastatin calcium, bexarotene, cinacalcet hydrochloride, clarithromycin, ezetimibe, fexofenadine hydrochloride, imatinib mesylate, ivabradine hydrochloride, ivabradine oxalate, letrozole, mecloxamine citrate, naratriptan hydrochloride, nitazoxanide, quetiapine, ropinirole hydrochloride, rosuvastatin calcium, saxagliptin monohydrate, silodosin, and temozolomide. Beyond its core manufacturing operations, the company offers a broad spectrum of services. These encompass early and late-phase drug development, process research and development, contract and API manufacturing, custom chemicals and synthesis, analytical development, regulatory support, specialized chemistry services, impurity profiling, isolation, discovery, identification, characterization, and project management. Founded in 1995, and headquartered in Manimajra, India, Ind-Swift Laboratories Limited also exports its products internationally.
Technical Analysis
Hikal Limited
―
Indoco Remedies Limited
―
Lincoln Pharmaceuticals Ltd
―
Solara Active Pharma Sciences Ltd.
―
Venus Remedies Limited
―